Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GSK Says China Revenues Fell 18% in Q4

publication date: Feb 5, 2014
GlaxoSmithKline reported that its Q4 China revenues dropped 18% year-over-year for its drugs and vaccines. Ordinarily, that would be a disaster. But given that the company’s sales were 61% lower in Q3, a decline of only 18% shows recovery. Overall, GSK’s China revenues were down 29% for the full year. The company’s Q4 report shows that the China fallout from GSK’s bribery scandal will be something it can weather. The ex-China part of its Emerging Markets revenue was up 5% in 2013. More details....

Stock Symbol: (NYSE GSK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital